Cara Therapeutics (NASDAQ:CARA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday.

According to Zacks, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. “

Other analysts have also issued reports about the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price target on shares of Cara Therapeutics in a research report on Thursday, October 4th. BidaskClub downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 1st. Canaccord Genuity set a $25.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Piper Jaffray Companies set a $27.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Finally, Janney Montgomery Scott initiated coverage on shares of Cara Therapeutics in a research note on Thursday, December 20th. They set a “buy” rating and a $13.36 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $25.54.

Shares of CARA stock traded down $0.04 during trading hours on Monday, hitting $15.35. The company’s stock had a trading volume of 419,662 shares, compared to its average volume of 584,631. The firm has a market capitalization of $603.11 million, a PE ratio of -8.25 and a beta of 2.95. Cara Therapeutics has a twelve month low of $11.46 and a twelve month high of $24.30.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.05). The firm had revenue of $5.06 million for the quarter, compared to analyst estimates of $4.72 million. Sell-side analysts expect that Cara Therapeutics will post -2.14 EPS for the current year.

In related news, CEO Derek T. Chalmers sold 15,825 shares of the company’s stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $12.53, for a total transaction of $198,287.25. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Derek T. Chalmers sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $18.78, for a total transaction of $375,600.00. Following the transaction, the chief executive officer now directly owns 991,392 shares in the company, valued at approximately $18,618,341.76. The disclosure for this sale can be found here. Insiders have sold 114,492 shares of company stock worth $1,695,732 in the last three months. Insiders own 6.70% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. raised its stake in Cara Therapeutics by 23.1% during the third quarter. BlackRock Inc. now owns 2,758,118 shares of the biopharmaceutical company’s stock worth $66,055,000 after purchasing an additional 516,870 shares during the period. Vanguard Group Inc raised its stake in Cara Therapeutics by 24.5% during the third quarter. Vanguard Group Inc now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after purchasing an additional 305,020 shares during the period. Vanguard Group Inc. raised its stake in Cara Therapeutics by 24.5% during the third quarter. Vanguard Group Inc. now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after purchasing an additional 305,020 shares during the period. Nexthera Capital LP raised its stake in Cara Therapeutics by 69.2% during the third quarter. Nexthera Capital LP now owns 737,303 shares of the biopharmaceutical company’s stock worth $17,658,000 after purchasing an additional 301,503 shares during the period. Finally, Marshall Wace LLP raised its stake in Cara Therapeutics by 29.1% during the third quarter. Marshall Wace LLP now owns 450,324 shares of the biopharmaceutical company’s stock worth $10,785,000 after purchasing an additional 101,398 shares during the period. 60.62% of the stock is currently owned by institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Recommended Story: Cost of Capital

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.